SIC
NVS icon

Samalin Investment Counsel’s Novartis NVS Stock Holding History

Samalin Investment Counsel’s Portfolio NVS Stock Details NVS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q1 		– Sell
-113
Closed -$10K – 404
2019
Q4 		$10K Buy
+113
New +$10.1K 0.01% 439

Other funds holding NVS

Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $295B AUM 31.6% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Mawer Investment Management
Mawer Investment Management Calgary, Alberta, Canada $15.4B AUM 10.9% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Samalin Investment Counsel's NVS Position: Q1 2020 in Review

Samalin Investment Counsel sold out of Novartis (NVS) in Q1 2020, closing a stake of 113 shares — an estimated $10K sold.

Samalin Investment Counsel first reported a position in NVS in Q4 2019 and held it in 1 quarter. The position peaked at $10K in Q4 2019. 1,133 funds tracked by Wall St. Rank hold NVS as of Q1 2020.

  • Samalin Investment Counsel reported no remaining Novartis position as of Q1 2020 after selling out during the quarter.
  • Samalin Investment Counsel sold 113 Novartis shares in Q1 2020, an estimated $10K.
  • Samalin Investment Counsel first reported a position in Novartis in Q4 2019 and held it in 1 quarter.
  • Samalin Investment Counsel's Novartis position peaked at $10K in Q4 2019.
  • 1,133 funds tracked by Wall St. Rank held Novartis as of Q1 2020.

Based on Samalin Investment Counsel's 13F filing for Q1 2020, filed 4 May 2020.